EHA 2021 | Genetic testing in CLL and the role of biomarkers
John Byrd, MD, Ohio State University, Columbus, OH, gives an overview of the use of biomarkers in the field of treatment of chronic lymphocytic leukemia (CLL), commenting on the impact of Bruton’s tyrosine kinase (BTK) inhibitors and the role of NOTCH mutations and Richter’s transformation. Dr Byrd also discusses the future role of biomarkers in the CLL space. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
John Byrd, MD, has received honoraria from AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium Therapeutics; has participated in a consultancy or advisory role for Acerta Pharma, Genentech, Pharmacyclics and Jazz Pharmaceuticals; and has received research funding from Acerta Pharma and Pharmacyclics.
